


ASH: Daratumumab beneficial for patients with multiple myeloma

December 13 2023, by Elana Gotkine



For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and

consolidation therapy and with lenalidomide maintenance therapy (D-VRd) improves progression-free survival. These findings were published online Dec. 12 in the *New England Journal of Medicine* to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in San Diego.

Pieter Sonneveld, M.D., Ph.D., from the Erasmus MC Cancer Institute in Rotterdam, Netherlands, and colleagues randomly assigned 709 transplantation-eligible patients with newly diagnosed multiple [myeloma](#) to receive D-VRd induction and consolidation therapy and lenalidomide maintenance therapy (D-VRd group) or VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group) in a phase 3 trial.

The researchers found that the risk for [disease progression](#) or death was lower in the D-VRd group than in the VRd group at a median follow-up of 47.5 months. The estimated percentage of patients with [progression-free survival](#) was 84.3 and 67.7 percent in the D-VRd and VRd groups, respectively, at 48 months (hazard ratio for disease progression or death, 0.42). The D-VRd group had a higher percentage of patients with a complete response or better (87.9 versus 70.1 percent) and a higher percentage of patients with minimal residual disease-negative status (75.2 versus 47.5 percent).

"These results further strengthen the existing evidence supporting the use of daratumumab in combination regimens for patients with newly diagnosed multiple myeloma," the authors write.

The study was partially funded by Janssen Research and Development, the manufacturer of daratumumab.

More information: Pieter Sonneveld et al, Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma,

New England Journal of Medicine (2023). [DOI: 10.1056/NEJMoa2312054](https://doi.org/10.1056/NEJMoa2312054)

[More Information](#)

Copyright © 2023 [HealthDay](#). All rights reserved.

Citation: ASH: Daratumumab beneficial for patients with multiple myeloma (2023, December 13) retrieved 27 April 2024 from <https://medicalxpress.com/news/2023-12-ash-daratumumab-beneficial-patients-multiple.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.